New Zealand Study
June 11, 2015, Sarasota
“The primary outcome measure of the study was a pharmacodynamic assessment of whether a single dose of orally administered anatabine citrate can acutely attenuate expression and/or production of pro-inflammatory mediators in human white blood cells, thus creating an anti-inflammatory effect. Follow up analysis is complete and the Company is expecting to provide a formal report in the third quarter.”
But the short bashers keep saying ““Yes the NZ is only about safety.”
But here is how the Merck Manual describes Pharmacodynamics
“Drug dynamics (pharmacodynamics) involves what a drug does to the body.
Drug dynamics describes the therapeutic effects of drugs (such as relief of pain and reduction of blood pressure) and their side effects. But drug dynamics also describes where (the site) and how (the mechanism) a drug acts on the body.”
Here are some facts
- The shorts have written hundreds of posts 24/7 trying to convince everyone that RCPI is a scam.
- The press has written dozens of negative articles spawning from JW’s interactions with the ex-Governor of Virginia and his DOJ Plea coping deal.
- Civil suits were filed claiming that false and misleading statements had been made.
- The negative press has been overwhelming.
If the shorts say they can’t figure out why the New Zealand Study results are important,
then they are LYING again!
For those who did their homework assignment, they will have discovered that SRQ Bio has been working with Rock Creek before April 2010.
In that time, how much do you think SRQ Bio has learned about anatabine citrate?
Who thinks it is an accident that Rock Creek Pharmaceuticals and SRQ Bio now reside at the same address after all that investigation into anatabine citrate?
The shorts are worried that the rise today will attract attention,
so the posting of LIES is rapidly increasing.
The shorts just can't accept the reality that the Clinical Trial in Europe just keeps marching forward.
The shorts don’t like it but the company continues to march forward toward phase II studies.
This quarter, the UK clinical trial is being used for time release and dose optimization and is expected to complete and generate preliminary results this quarter.
Phase II studies are expected to get underway next quarter.
For more information, check out the June Investor presentation located on the RCPI web site. Look under the Presentations and Webinars section.
Google - Roskamp Institute to Begin Human Alzheimer's Clinical Trials…
SARASOTA, Fla., Oct. 7 /PRNewswire-USNewswire/ -- Today the Roskamp Institute said that it is pleased to announce that it will soon begin clinical trials of RCP-006, a compound found in tobacco, for the treatment of Alzheimer's disease. The compound was developed by Rock Creek Pharmaceuticals, a subsidiary of Star Scientific in Virginia, and made available to Roskamp through its affiliate, SRQ Bio, LLC.
SRQ Bio, LLC, a for-profit affiliate of the Roskamp Institute, has a financial interest in Star Scientific. In April 2010, Star Scientific issued to SRQ Bio, LLC 100,000 shares of common stock in a private placement….
So…SRQ Bio was involved with the Alzheimer’s study all the way back in Oct 2010.
Now the two companies share the same address.
Well Well Well,,, isn’t that interesting bashers?
If anyone is interesting in understanding how the clinical trial in the UK, currently underway, is being used to develop a time release version and optimize the formulation, then -
Google: Quotient Clinical – RapidFACT
Preliminary results of the UK trial are expected this quarter
From the last Clinical Trial Update
“Subsequently, the Company expects to conduct Part Three of the study comprised of a double-blind, placebo-controlled, seven-day multiple dose study of the optimal formulation in healthy subjects and is targeting study completion and generating preliminary results in the third quarter 2015.”
The shorts don't want longs to read the National Center for Biotechnology Information (NCBI) article on STAT3 and NF-kB collaboration and crosstalk in cancer?
After you read that article, in combination with the NZ trial press release,
you will UNDERSTAND why the shorts don't want anyone reading that article.
1) Demonstrates a process used to measure anti-inflammatory response
2) The results were positive
3) The process can be used to OPTIMIZE a time release formulation in EU trial
4) The results can be used to help attract development PARTNERS.
That is just four reasons why the NZ trial is important, and there is more,
which the Shorts won't like
In the last Quarterly update on March 12th, the company press release said “Subsequently, the Company expects to conduct Part Three of this study comprised of a double-blind, placebo-controlled, seven-day multiple dose study of the optimal formulation in healthy subjects and is targeting study completion and generating preliminary results by the end of the second quarter 2015.”
With the massive volume today, I wonder if those preliminary results are about to be released?
When FIVE Institutions enter into a purchase agreement how does that affect Institutional Ownership?
After answering that, why would Institutional Ownership be rising if this stock is worthless as the bashers try to convince everyone?
I don't think this new crop of shorts understand that a big part of the EU trial currently underway is to OPTIMIZE a time release formulation.
The last clinical trial update that RCPI released for the UK trial says that besides identifying an optimal formulation, “Exploratory pharmacodynamic (PD) outcome measures are also being assessed.”
Here are the facts
Twicey knows full well that last quarter before the direct registered offering, the Nasdaq web site showed Institutional Ownership at over 18 percent.
Nasdaq adjusted the Institutional Ownership after the Direct Registered Offering to reflect the revised share count.
If you look TODAY at the Nasdaq Web site under institutional ownership (page 4), you will see that Goldman Capital Management sold out 661,000 shares. About three months earlier, when the NASDAQ web site showed Goldman Capital Management owned 661,000 shares, Twicey started shouting oh this must be an error, that wasn’t reverse split adjusted, blaa, blaa, blaa. So if Twicey thinks it’s still an error even today, he can go cry to Nasdaq.
And where is ociferdibble?
Does anyone remember back in April when ociferdibble was posting this about Institutional Ownership?
ociferdibble - Apr 15, 2015 9:01 AM
Institutional Ownership View RCPI Ownership
Institutional Holdings 00.30%
Total Number of Holders 70
Total Shares Held 599,776
Total Value of Holdings 1,673,375
Net Activity (156,879)
So as much a Twicey and ociferdibble hate it, Institutional Ownership has risen from near zero to 10.71% as of today.
If you don’t like it, go complain to Nasdaq!
Second Quarter data is out (as listed on Nasdaq), and 9 out of the top 10 Institutional Investors ADDED shares in Second Quarter.
Ameriprise Financial Inc 6/30/2015 237,851 adds - 49,654
Blackrock Institutional Trust 6/30/2015 198,973 adds - 37,564
Tenor Capital Management 6/30/2015 185,911 adds - 185,911 New
Vanguard Group Inc 6/30/2015 177,204 adds - 10,427
Susquehanna International 6/30/2015 131,927 adds - 122,840
Talkot Capital 6/30/2015 75,291 sells - ONE share
KCG Holdings 6/30/2015 74,213 adds - 72,501
Tower Research 6/30/2015 18,401 adds - 18,401 New
Chelsea Counsel 6/30/2015 16,300 adds – 0
Morgan Stanley 6/30/2015 13,400 adds – 10,013
One Institution sold ONE share.
The Top Ten added 507,311 shares in Q2.
Then there was Goldman Capital who added MASSIVELY in the first quarter (610,920 shares) for a total of 661,000 shares, but then sold out in second quarter. I bet there is a wild story behind that one. By the way, how did Goldman Capital acquire 610,920 shares in the first quarter while the stock price was declining?
Did Goldman Capital get those shares from a share transfer from some other shareholder?
Anyways - despite the Goldman Capital mystery show, 9 out of the top 10 institutional investors have been adding in second quarter.
By the way, early this year the bashers like ociferdibble was laughing about the institutional ownership being close to zero.
Hey ociferdibble, why are 9 of the top 10 institutions continuing to add?
Twicey spent all weekend trying to spin the Nasdaq data in an attempt
to hide the fact that Institutional Ownership is rising this year.
Now Twicey is trying to spin the fact that RCPI has hired a part time CFO
who in the past has worked for a company that specializes in this.
Google - Tatum CFO Partners
Until RCPI gets thru the clinical trial process, they don't need a full time CFO.
Save money, and put it where it most makes sense.
Clinical Trails and Research.
NEW YORK, July 20, 2015 /PRNewswire/-- Rodman & Renshaw Conferences, LLC, today announced that – former United States Secretary of State and Nobel Peace Laureate – Henry A. Kissinger will present the keynote address for the 2015 Rodman & Renshaw Annual Global Investment Conference...
Simultaneously, Drum, Twicey, and Tina's broker are scheduled speak from some undisclosed basement about multi-personality disorder.